Level 1 — Absolute Beginner
Scientists found something new. A drug for back injuries might also help with Alzheimer's disease.
Alzheimer's disease makes people forget things. It happens mostly to older people.
The drug is called KCL-286. Scientists at King's College London gave it to mice. It fixed damage inside brain cells.
This drug already passed a safety test for humans. That means it could be tested for Alzheimer's faster than a brand new drug.
- scientist
- a person who studies and learns about the world through experiments
- drug
- a medicine used to treat an illness
- injury
- damage or harm done to a part of the body
- disease
- an illness that affects the body
- forget
- to fail to remember something
- mice
- small animals often used in science experiments
- damage
- harm that makes something not work correctly
- safety test
- a test that checks if something is not harmful
Level 2 — Elementary
Researchers at King's College London have discovered that a drug originally developed for spinal cord injuries may also help fight Alzheimer's disease.
The drug, called KCL-286, was tested on mice that had signs of Alzheimer's. It repaired damaged DNA inside brain cells and reduced swelling in the brain.
Unlike many Alzheimer's treatments that focus only on one type of brain buildup, KCL-286 worked on several problems at the same time.
Because KCL-286 already passed an early safety trial in humans for spinal injuries, scientists believe it could move into Alzheimer's testing more quickly than a completely new medicine.
- researcher
- a person who carefully studies a subject to discover new information
- spinal cord
- the bundle of nerves running through the backbone
- DNA
- the material inside cells that carries genetic information
- brain cell
- a cell, such as a neuron, that makes up the brain
- swelling
- an increase in size caused by inflammation
- buildup
- an accumulation of a substance over time
- treatment
- medical care given to fight an illness
- trial
- a scientific test used to check if something works or is safe
Level 3 — Intermediate
Researchers at King's College London have found that KCL-286, a drug originally developed to treat spinal cord injuries, reduced multiple hallmarks of Alzheimer's disease in a mouse model, according to a study published in the journal FEBS Open Bio.
Mice treated with KCL-286 showed significantly fewer DNA double-strand breaks in their neurons than untreated mice, a type of genetic damage frequently observed in the brains of Alzheimer's patients. The drug also reduced inflammation throughout the brain.
Unlike many experimental Alzheimer's treatments that target a single mechanism, such as amyloid or tau buildup, KCL-286 activates a protein in the retinoic acid pathway, the series of chemical reactions the body uses to process vitamin A, which in turn enhances DNA repair by upregulating a gene called BRCA1.
Because KCL-286 has already cleared an initial Phase 1 human safety trial for its original spinal cord indication, researchers believe it could advance into Alzheimer's clinical testing considerably faster than a novel compound starting from scratch.
- hallmark
- a distinctive feature or characteristic typical of something
- double-strand break
- a type of DNA damage in which both strands of the double helix are severed
- neuron
- a nerve cell that transmits signals in the brain and body
- mechanism
- the process by which something works or happens
- pathway
- a sequence of chemical reactions in the body leading to a specific outcome
- upregulate
- to increase the activity or expression of a gene or protein
- indication
- a medical condition for which a treatment is approved or intended
- compound
- a substance formed from chemical elements, such as an experimental drug
Level 4 — Advanced
Researchers at King's College London have determined that KCL-286, a drug originally developed to treat spinal cord injuries, attenuated multiple hallmarks of Alzheimer's disease in a mouse model, according to findings published in the journal FEBS Open Bio.
Mice administered KCL-286 exhibited significantly fewer DNA double-strand breaks within their neurons relative to untreated controls, a form of genomic damage frequently implicated in the neuropathology of Alzheimer's patients. The compound also attenuated neuroinflammation more broadly across the brain.
In contrast to many experimental Alzheimer's therapeutics that target a singular mechanism, such as amyloid-beta or tau aggregation, KCL-286 activates a protein within the retinoic acid pathway, the cascade of biochemical reactions the body employs to metabolize vitamin A, thereby enhancing DNA repair capacity via upregulation of the gene BRCA1.
Because KCL-286 has already cleared an initial Phase 1 human safety trial for its original spinal cord indication, researchers anticipate it could advance into Alzheimer's clinical testing considerably more expeditiously than a novel compound developed from first principles, potentially compressing a development timeline that typically spans well over a decade.
- attenuate
- to reduce the severity, intensity, or force of something
- genomic
- relating to the complete set of genetic material in an organism
- neuropathology
- the study of diseases affecting the nervous system
- aggregation
- the clumping together of molecules, such as misfolded proteins
- cascade
- a sequence of processes or reactions, each triggering the next
- metabolize
- to chemically break down or process a substance in the body
- expeditiously
- in a way that is done efficiently and speedily
- compress
- to reduce the size, duration, or scope of something
Talk about this article with KatePractice this story's vocabulary in a real spoken conversation with your AI tutor